Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8223709 | 0.90 | ALDH1A1 (0.39) | ALDH1A1HTTPOLB | |
| SCHEMBL679738 | 0.89 | POLB (0.38) | ALDH1A1HTTPOLB | |
| SCHEMBL14295744 | 0.88 | AKT3 (0.38) | ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL681788 | 0.86 | POLB (0.35) | ALDH1A1HTTPOLB | |
| SCHEMBL683339 | 0.85 | CYP1A2 (0.38) | ALDH1A1HTTPOLBCYP1A2SMN1; SMN2 | |
| SCHEMBL2738723 | 0.78 | AKT3 (0.38) | ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL12168931 | 0.77 | GAA (0.38) | ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL12188390 | 0.77 | FPR2 (0.40) | ALDH1A1POLBCYP1A2SMN1; SMN2 | |
| SCHEMBL681038 | 0.75 | AKT3 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL2739041 | 0.75 | ALDH1A1 (0.37) | ALDH1A1HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | ALDH1A1 1715/4885HTT 2076/4885POLB 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.